Bär & Karrer advised Neva SGR, the Intesa Sanpaolo Group’s venture capital company, a full subsidiary of Intesa Sanpaolo Innovation Center, in a CHF 79 million (€84 million) funding round for NUCLIDIUM, a Swiss-German biotechnology company specializing in next-generation radiopharmaceuticals for cancer.

The investment will enable NUCLIDIUM to accelerate the development of its
innovative proprietary theranostic platform, which provides a combined approach to cancer diagnosis and treatment. Additionally, the company is preparing to expand its worldwide production network, grow its international team, and strengthen strategic collaborations with hospitals and academic centres, initially across Europe and North America.

Bär & Karrer acted as Swiss legal advisor to Neva throughout this transaction. The team included Raphael Annasohn, Luana Stämpfli (both Venture Capital/M&A), Matthias Bizzarro (Tax), as well as Özden Omürcan (Notarial Services).

Global law firm Dentons supported Neva on Italian law matters with a team led by partner Antonio Legrottaglie, assisted by associate Paolo Piscopo.
Neva was also supported by the in-house legal team of the Intesa Sanpaolo Group, Massimiliano Canelli and Marta Cubisino.

For further information please contact:
Media Relations, Eric Stupp
Tel: +41 58 261 50 00
Email: [email protected]

More from Bär & Karrer Ltd.